Premium
Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy
Author(s) -
Mallinson Joanne E.,
ConstantinTeodosiu Dumitru,
Sidaway James,
Westwood F. Russell,
Greenhaff Paul L.
Publication year - 2009
Publication title -
the journal of physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.802
H-Index - 240
eISSN - 1469-7793
pISSN - 0022-3751
DOI - 10.1113/jphysiol.2008.164699
Subject(s) - simvastatin , pdk4 , medicine , endocrinology , foxo1 , muscle atrophy , protein kinase b , chemistry , statin , myostatin , myopathy , skeletal muscle , phosphorylation , atorvastatin , glycogen synthase , glycogen , gene expression , biochemistry , gene
Statins are used clinically for cholesterol reduction, but statin therapy is associated with myopathic changes through a poorly defined mechanism. We used an in vivo model of statin myopathy to determine whether statins up‐regulate genes associated with proteasomal‐ and lysosomal‐mediated proteolysis and whether PDK gene expression is simultaneously up‐regulated leading to the impairment of muscle carbohydrate oxidation. Animals were dosed daily with 80 mg kg −1 day −1 simvastatin for 4 ( n = 6) and 12 days ( n = 5), 88 mg kg −1 day −1 simvastatin for 12 days ( n = 4), or vehicle (0.5% w/v hydroxypropyl‐methylcellulose and 0.1% w/v polysorbate 80; Control, n = 6) for 12 days by oral gavage. We found, in biceps femoris muscle, decreased Akt Ser473 , FOXO1 Ser253 and FOXO3a Ser253 phosphorylation in the cytosol ( P < 0.05, P < 0.05, P < 0.001, respectively) and decreased phosphorylation of FOXO1 in the nucleus after 12 days simvastatin when compared to Control ( P < 0.05). This was paralleled by a marked increase in the transcription of downstream targets of FOXO, i.e. MAFbx ( P < 0.001), MuRF‐1 ( P < 0.001), cathepsin‐L ( P < 0.05), PDK2 ( P < 0.05) and PDK4 ( P < 0.05). These changes were accompanied by increased PPARα ( P < 0.05), TNFα ( P < 0.01), IL6 ( P < 0.01), Mt1A ( P < 0.01) mRNA and increased muscle glycogen ( P < 0.05) compared to Control. RhoA activity decreased after 4 days simvastatin ( P < 0.05); however, activity was no different from Control after 12 days. Simvastatin down‐regulated PI3k/Akt signalling, independently of RhoA, and up‐regulated FOXO transcription factors and downstream gene targets known to be implicated in proteasomal‐ and lysosomal‐mediated muscle proteolysis, carbohydrate oxidation, oxidative stress and inflammation in an in vivo model of statin‐induced myopathy. These changes occurred in the main before evidence of extensive myopathy or a decline in the muscle protein to DNA ratio.